Protara Therapeutics (TARA) Assets Average (2014 - 2026)

Protara Therapeutics (TARA) has 13 years of Assets Average data on file, last reported at $200.7 million in Q1 2026.

• On a quarterly basis, Assets Average rose 14.68% year-over-year to $200.7 million in Q1 2026; TTM through Mar 2026 was $200.7 million, a 14.68% increase from a year earlier, with the FY2025 full-year figure at $195.5 million, up 50.12% from the prior year.
• Assets Average for Q1 2026 stood at $200.7 million, up from $177.1 million in the prior quarter.
• Over the last five years, Assets Average for TARA reached as high as $200.7 million in Q1 2026 and fell as low as $73.5 million in Q1 2024.
• Historically, Assets Average has averaged $132.6 million across 5 years, with a median of $137.8 million in 2024.
• Across the five-year window, Assets Average sank 39.5% in 2023 and jumped 137.96% in 2025, its largest moves.
• Year by year, Assets Average stood at $130.9 million in 2022, then slumped by 36.07% to $83.7 million in 2023, then soared by 64.58% to $137.8 million in 2024, then increased by 28.51% to $177.1 million in 2025, then grew by 13.35% to $200.7 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $200.7 million in Q1 2026, $177.1 million in Q4 2025, and $150.8 million in Q3 2025.